Development of an anti-inflammatory diet for first-episode psychosis (FEP): a feasibility study protocol

被引:0
作者
Kennedy, Leda [1 ]
Holt, Tiffany [2 ]
Hunter, Anna [2 ]
Golshan, Shahrokh [2 ]
Cadenhead, Kristin [1 ]
Mirzakhanian, Heline [1 ]
机构
[1] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92093 USA
[2] Univ Calif San Diego, Ctr Integrat Med, San Diego, CA USA
来源
FRONTIERS IN NUTRITION | 2024年 / 11卷
关键词
first-episode psychosis; inflammation; dietary intervention; nutrition; protocol; 1ST EPISODE PSYCHOSIS; MENTAL-ILLNESS; KETOGENIC DIET; FOLLOW-UP; SCHIZOPHRENIA; SYMPTOMS; INTERVENTIONS; INFLAMMATION; MODULATE; OUTCOMES;
D O I
10.3389/fnut.2024.1397544
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Evidence suggests inflammation plays a role in the pathophysiology of psychosis even in early illness, indicating a potential avenue for anti-inflammatory interventions that simultaneously address high rates of metabolic disease in this population. The aim of this study is to design a novel anti-inflammatory diet intervention (DI) that is feasible to implement in a first-episode psychosis (FEP) population. Methods: Eligible FEP Participants are aged 15-30. The DI is currently being refined through a multi-phase process that includes the recruitment of focus groups that provide insight into feasibility of measures and nutritional education, as well as the implementation of the DI. The phases in the study are the Development Phase, Formative Phase, and the Feasibility Phase. Results: The Development phase has resulted in the creation of a flexible DI for FEP based on existing research on nutritional health and informed by providers. This study has just completed the Formative phase, recruiting eligible participants to join focus groups that gleaned information about dietary habits, preferences, and food environments to further refine the DI. Conclusion: Findings from earlier phases have advised the current Feasibility Phase in which this novel DI is being administered to a small cohort of FEP participants (N = 12) to determine acceptability of the DI from a lived experience perspective. Naturalistic changes in inflammatory biomarkers, metabolic health, and symptoms will also be measured.
引用
收藏
页数:13
相关论文
共 89 条
  • [1] A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation
    Aas, Monica
    Dazzan, Paola
    Mondelli, Valeria
    Melle, Ingrid
    Murray, Robin M.
    Pariante, Carmine M.
    [J]. FRONTIERS IN PSYCHIATRY, 2014, 4
  • [2] Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder
    Abdel-Baki, Amal
    Thibault, Dominic
    Medrano, Sofia
    Stip, Emmanuel
    Ladouceur, Martin
    Tahir, Ramzan
    Potvin, Stephane
    [J]. EARLY INTERVENTION IN PSYCHIATRY, 2020, 14 (01) : 69 - 79
  • [3] A DEPRESSION RATING-SCALE FOR SCHIZOPHRENICS
    ADDINGTON, D
    ADDINGTON, J
    SCHISSEL, B
    [J]. SCHIZOPHRENIA RESEARCH, 1990, 3 (04) : 247 - 251
  • [4] Improving vocational outcomes in first-episode psychosis by addressing cognitive impairments using Cognitive Adaptation Training
    Allott, Kelly A.
    Killackey, Eoin
    Sun, Pamela
    Brewer, Warrick J.
    Velligan, Dawn I.
    [J]. WORK-A JOURNAL OF PREVENTION ASSESSMENT & REHABILITATION, 2017, 56 (04): : 581 - 589
  • [5] Andrew AS, 2017, INT J MOL SCI, V18, DOI [10.3390/ijms18030651, 10.3390/ijms18030535]
  • [6] Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review
    Arroll, Megan Anne
    Wilder, Lorraine
    Neil, James
    [J]. NUTRITION JOURNAL, 2014, 13
  • [7] Diet and Psychosis: A Scoping Review
    Aucoin, Monique
    LaChance, Laura
    Cooley, Kieran
    Kidd, Sean
    [J]. NEUROPSYCHOBIOLOGY, 2020, 79 (01) : 20 - 42
  • [8] Allostatic load is associated with psychotic symptoms and decreases with antipsychotic treatment in patients with schizophrenia and first-episode psychosis
    Berger, Maximus
    Juster, Robert-Paul
    Westphal, Sabine
    Amminger, G. Paul
    Bogerts, Bernhard
    Schiltz, Kolja
    Bahn, Sabine
    Steiner, Johann
    Sarnyai, Zoltan
    [J]. PSYCHONEUROENDOCRINOLOGY, 2018, 90 : 35 - 42
  • [9] Antipsychotics can modulate the cytokine profile in schizophrenia: Attenuation of the type-2 inflammatory response
    Borovcanin, Milica
    Jovanovic, Ivan
    Radosavljevic, Gordana
    Dejanovic, Slavica Djukic
    Stefanovic, Vesna
    Arsenijevic, Nebojsa
    Lukic, Miodrag L.
    [J]. SCHIZOPHRENIA RESEARCH, 2013, 147 (01) : 103 - 109
  • [10] Nutraceuticals in Psychiatric Disorders: A Systematic Review
    Bozzatello, Paola
    Novelli, Roberta
    Montemagni, Cristiana
    Rocca, Paola
    Bellino, Silvio
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (09)